CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
We received an updated WNV package insert; please note the manufacturer and license number has been ...